# Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

> **NCT01433926** · — · COMPLETED · sponsor: **Asociación para el Progreso de la Oncología en Málaga** · enrollment: 114 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01433926
- **Lead sponsor:** Asociación para el Progreso de la Oncología en Málaga
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-09
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2011-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433926, "Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01433926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*